Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.25
Bid: 10.50
Ask: 12.00
Change: 2.40 (26.67%)
Spread: 1.50 (14.286%)
Open: 9.00
High: 11.40
Low: 9.00
Prev. Close: 9.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Redx Pharma plc

17 Mar 2020 14:30

RNS Number : 4869G
Redx Pharma plc
17 March 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc ("Redx")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(d) Is the discloser the offeror or the offeree?

OFFEROR / OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

17 March 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

n/a

n/a

(2) Cash-settled derivatives:

 

n/a

n/a

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

n/a

n/a

 

TOTAL:

n/a

n/a

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interest of Redx Directors and connected advisers in Redx shares:

Name

Number of Shares

% of issued share capital

Iain Ross

600,000

0.32

Dr. Bernhard Kirschbaum

50,000

0.02

Peter Presland

120,000

0.06

WG Partners LLP

114,593

0.06

 

Interest of Redx Directors in options over Redx shares:

Name

No. of options

Exercise price

Vesting date

Expiry date

Lisa Anson

600,000

13.75p

4 June 2018

3 June 2028

Lisa Anson

600,000

20p

4 June 2018

3 June 2028

Lisa Anson

600,000

27p

4 June 2019

3 June 2028

Lisa Anson

600,000

35p

4 June 2019

3 June 2028

Lisa Anson

600,000

42.5p

4 June 2020

3 June 2028

Lisa Anson

600,000

50p

4 June 2020

3 June 2028

Dr. James Mead

200,000

13.75p

13 February 2019

12 February 2029

Dr. James Mead

200,000

20p

13 February 2019

12 February 2029

Dr. James Mead

200,000

27p

13 February 2020

12 February 2029

Dr. James Mead

200,000

35p

13 February 2020

12 February 2029

Dr. James Mead

200,000

42.5p

13 February 2021

12 February 2029

Dr. James Mead

200,000

50p

13 February 2021

12 February 2029

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES/NO

Supplemental Form 8 (SBL)

YES/NO

 

 

Date of disclosure:

17 March 2020

Contact name:

James Mead

Telephone number:

01625 496 609

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFLFLSVSIDLII
Date   Source Headline
28th Jan 20207:00 amRNSStatement re Rule 2.6 Extension
24th Jan 202011:05 amRNSHolding(s) in Company
24th Jan 20209:40 amRNSHolding(s) in Company
23rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Jan 20208:32 amRNSForm 8.3 - Redx Pharma plc
22nd Jan 20205:04 pmRNSPaul John Blackmore - Form 8.3 - RedX Pharma
22nd Jan 202012:49 pmRNSForm 8.3 - RedX Pharma PLC
22nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
21st Jan 20201:23 pmRNSResult of General Meeting
16th Jan 20209:25 amRNSForm 8.3 - Redx Pharma plc
15th Jan 20204:20 pmRNSForm 8.3 - Redx Pharma PLC
15th Jan 20203:17 pmRNSForm 8.3 - Redx Pharma Plc
15th Jan 20202:57 pmRNSForm 8.3 - Redx Pharma plc
10th Jan 20207:56 amRNSForm 8.3 - Redx Pharma plc
9th Jan 20202:14 pmRNSPublic Opening Position Disclosure
9th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
9th Jan 20207:00 amRNSRXC007 nominated as drug development candidate
7th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
6th Jan 20202:16 pmRNSForm 8.3 - Redx Pharma
6th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Jan 20204:14 pmRNSPosting of Circular to Shareholders
3rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Jan 20202:44 pmRNSForm 8.3 - Redx Pharma plc
2nd Jan 202012:57 pmGNWForm 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC
2nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
31st Dec 20197:00 amRNSLoan Capitalisation, GM Notice and Possible Offer
19th Nov 20197:00 amRNSRedx & Medicines Discovery Catapult awarded grant
7th Nov 20193:30 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSRXC006 poster presentation at ERS Congress
19th Aug 20197:00 amRNSFirst cohort of patients dosed in RXC004 study
18th Jul 201910:24 amEQSHardman & Co Research: RedX Pharma (REDX): Pan-RAF agreement strengthens balance sheet
11th Jul 20191:41 pmEQSHardman & Co Research: Redx Pharma (REDX): Phase I trial resumed
10th Jul 20197:00 amRNSSale of pan-RAF inhibitor programme
10th Jun 20197:01 amRNSInterim Results for six months ended 31 March 2019
10th Jun 20197:00 amRNSShort-term Debt Funding Secured
3rd May 201911:34 amRNSUpdate on Plans to Strengthen Balance Sheet
29th Mar 20197:00 amRNSRedx to present two posters at AACR 2019
28th Feb 20197:00 amRNSIssue of Warrants and Change to Lease Agreement
14th Feb 20197:00 amRNSDirectorate Update
12th Feb 20197:00 amRNSNew in vivo data on ROCK2
6th Feb 201911:25 amRNSReceipt of Outstanding Loan
31st Jan 20197:00 amRNSDeinove return rights to Redx Programme
23rd Jan 201911:25 amRNSResults of Annual General Meeting
21st Jan 20197:00 amRNSRXC004 Trial Approval
10th Jan 20192:05 pmRNSSecond Price Monitoring Extn
10th Jan 20192:00 pmRNSPrice Monitoring Extension
3rd Jan 20197:00 amRNSRedx to present at 2019 Biotech Showcase event
28th Dec 201811:47 amRNSPublication of Annual Report and Accounts
30th Nov 20188:45 amEQSHardman & Co Research: RedX Pharma (REDX): RXC006: First fibrosis development candidate
30th Nov 20187:00 amRNSFirst RXC006 data for treatment of fibrosis

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.